Insights from the ESMO Gynecological Cancers Congress

Mansoor Raza Mirza, MD, Copenhagen University Hospital, Denmark

Conference Coverage

Beyond Immunotherapy Treatment for Patients With Recurrent Metastatic Endometrial Cancer

02/24/2023

At the 2023 ESMO Gynecological Cancers Congress, Mansoor Raza Mirza, MD, discusses the role of HER2, p53, and other molecular targets in treating patients with recurrent, metastatic endometrial cancer.

At the 2023 ESMO Gynecological...

02/24/2023

Oncology

Conference Coverage

Impact of BRCA Mutation Location on PARP Inhibitor Efficacy for Patients with Advanced Ovarian Cancer

02/23/2023

According to study results presented at the 2023 ESMO Gynecological Cancers Congress, the location and type of BRCA mutation may impact the effectiveness of PARP inhibitor treatment for patients with advanced ovarian cancer.

According to study results...

02/23/2023

Oncology

Conference Coverage

Optimal Treatment Modality for Patients With Advanced Cervical Cancer

02/23/2023

Derek Cowsert ;

Data presented at the 2023 ESMO Gynecological Cancers Congress shows survival outcomes were improved among patients with late-stage cervical cancer who received adjuvant chemoradiotherapy compared with other treatment modalities.

Data presented at the 2023 ESMO...

02/23/2023

Oncology

Conference Coverage

Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer

02/23/2023

Derek Cowsert ;

According to study results presented at the 2023 ESMO Gynecological Cancers Congress, patients with recurrent or metastatic cervical cancer treated with tisotumab vedotin experienced clinically meaningful and durable anti-tumor activity.

According to study results...

02/23/2023

Oncology

Insights from the ESMO Gynecological Cancers Congress

Specialties

Events

Year Round Education

HMP Global Products